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Abstract
Introduction: There is a sex difference in the risk of ischemic acute kidney injury (AKI), and estrogen mediates the
protective effect of female sex. We previously demonstrated that preprocedural chronic restoration of physiologic
estrogen to ovariectomized female mice ameliorated AKI after cardiac arrest and cardiopulmonary resuscitation
(CA/CPR). In the present study, we hypothesized that male mice and aged female mice would benefit from
estrogen administration after CA/CPR. We tested the effect of estrogen in a clinically relevant manner by
administrating it after CA/CPR.
Methods: CA/CPR was performed in young (10–15 weeks), middle-aged (43–48 weeks), and aged (78–87 weeks)
C57BL/6 male and female mice. Mice received intravenous 17β-estradiol or vehicle 15 min after resuscitation. Serum
chemistries and unbiased stereological assessment of renal injury were completed 24 h after CA. Regional renal
cortical blood flow was measured by a laser Doppler, and renal levels of estrogen receptor alpha (ERα) and G
protein-coupled estrogen receptor (GPER) were evaluated with immunoblotting.
Results: Post-arrest estrogen administration reduced injury in young males without significant changes in renal
blood flow (percentage reduction compared with vehicle: serum urea nitrogen, 30 %; serum creatinine (sCr), 41 %;
volume of necrotic tubules (VNT), 31 %; P < 0.05). In contrast, estrogen did not affect any outcomes in young
females. In aged mice, estrogen significantly reduced sCr (80 %) and VNT (73 %) in males and VNT (51 %) in
females. Serum estrogen levels in aged female mice after CA/CPR were the same as levels in male mice. With age,
renal ERα was upregulated in females.
Conclusions: Estrogen administration after resuscitation from CA ameliorates renal injury in young males and aged
mice in both sexes. Because injury was small, young females were not affected. The protective effect of exogenous
estrogen may be detectable with loss of endogenous estrogen in aged females and could be mediated by
differences in renal ERs. Post-arrest estrogen administration is renoprotective in a sex- and age-dependent manner.
Introduction
Acute kidney injury (AKI) is a common complication of
perioperative illness, and mortality is up to 70 %. In non-
cardiac surgical patients, the incidence is 1 %, conferring
a seven- to eight-fold increment in mortality. The most
common cause of hospital-acquired AKI is whole-body
hypoperfusion [1–5], which is also independently associ-
ated with perioperative AKI.
Overall, men are more likely to experience AKI than
women [6, 7]. Clinical data suggest that low estrogen
states are associated with increased risk of AKI [8, 9].
Data from animal models indicate that sex hormones
mediate AKI; androgen and testosterone enhance the
susceptibility to AKI, and estrogen is a protective factor
[10, 11]. We previously demonstrated in mice that
females enjoy relative protection from AKI after whole-
body ischemia-reperfusion injury, removal of physiologic
estrogen worsens AKI, and preprocedural restoration
of physiologic estrogen to ovariectomized female mice
restores the protected state [12, 13].
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Although estrogens have been studied widely, whether
estrogen is efficacious when administered after whole-
body ischemia-reperfusion and whether such protection
can be observed in males as well as females with intact
ovaries have not been determined. Therefore, to gain in-
sights into the role of estrogen as a treatment option, we
determined whether a single injection of estrogen, ad-
ministered on recovery from cardiac arrest and cardio-
pulmonary resuscitation (CA/CPR), improves AKI in
both sexes and whether the effect is dependent on renal
blood flow. It is relevant to administer estrogen in acute
phase after ischemic insult in the aspect of investigating
estrogen as a therapeutic agent since clinically CA is
frequently unheralded, and therefore therapy is applied
following resuscitation.
Clinical trials of ischemia-protective strategies proven
in mice may have failed in the past because of the reli-
ance on young mice [14-16]. Both experimental and
clinical studies demonstrate the strong linkage between
aging and AKI [17-19]. Clinical data suggest that women
enjoy protection from AKI in general but not when
undergoing cardiac and vascular surgery, settings in
which patients are older than the overall surgical popu-
lation [20]. This bimodal risk distribution may be a
phenomenon of the menopause and changing exposure
to estrogen with age. However, few studies have ad-
dressed effect modifications of aging on the association
between sex and AKI. Therefore, other important ques-
tions are whether the advantage of females against AKI
after whole-body ischemia is lost with age and whether
this is modulated by estrogen.
Together, the major aims of the present study were (1)
to determine whether post-arrest administration of
estrogen reduces AKI following CA/CPR in both sexes
and (2) to investigate whether aged females, the clinical
population with greatest AKI risk, lose the beneficial ef-
fect of female sex or benefit from post-arrest administra-
tion of estrogen or both. A further aim was to determine
whether estrogen receptor (ER) populations in the kid-
ney, unaffected by pre-arrest hormonal manipulation,
might change with age.
Methods
All experimental protocols involving animals were con-
ducted at Oregon Health & Science University in Portland,
Oregon. All animal experiments were conducted in con-
formity with the National Institutes of Health guidelines
for the care and use of animals in research and were specif-
ically approved by the Oregon Health & Science University
Institutional Animal Care and Use Committee.
Animals and experimental groups
Male and female C57BL/6 mice were obtained from
Charles River Laboratories (Boston, MA, USA). We used
young mice (10–15 weeks), middle-aged mice (43–48
weeks), and aged mice (78–87 weeks). Experimental
animals were randomized to 17β-estradiol or vehicle
treatment and subsequently underwent experimental
procedures.
In vivo whole-body ischemia-reperfusion (CA/CPR)
We performed normothermic CA/CPR as previously
described [12, 13, 21, 22] Briefly, mice were anesthe-
tized with 4 % isoflurane in a 2:1 air-to-oxygen mixture,
and anesthesia was maintained with 1 %–2 % isoflurane.
After tracheal intubation with a 22-guage Teflon catheter
(BD, Franklin, NJ, USA), animals were mechanically venti-
lated and the electrocardiogram (EKG) was monitored
continuously. For drug administration, a PE-10 catheter
was inserted into the right internal jugular vein. Rectal
temperature was maintained 37 ± 5 °C throughout the ex-
periment with a digitally controlled lamp (Cole Parmer,
Vernon Hills, IL, USA). CA was induced with 50 μl of
0.5 M potassium chloride and confirmed by isoelectric
EKG signal and absence of visible cardiac contraction on
the chest wall. At onset of CA, the endotracheal tube was
disconnected. Seven and a half minutes after onset of CA,
mechanical ventilation resumed. Eight minutes after onset
of CA, chest compressions were delivered by a finger at a
rate of 300 per minute, and epinephrine in 0.9 % sodium
chloride solution, 11–16 μg (0.7–1.0 ml), was adminis-
tered intravenously. Return of spontaneous circulation
(ROSC) was confirmed by reappearance of electrical activ-
ity on the EKG and visible cardiac contractions on the
chest wall. Animals were extubated when their spontan-
eous respiratory rate reached more than 60 breaths per
minute and then were moved to a recovery cage.
Preparation of 17β-estradiol and correspondent vehicle
A previous study performed in the same laboratory
demonstrated that injection of 0.5 μg of 17β-estradiol
resulted in a peak of serum estradiol levels shortly
after administration followed by a decrease to physio-
logic levels within 1 h in male C57BL/6 mice [23].
We therefore administered 0.5, 5, and 10 μg of 17β-
estradiol to investigate whether any renoprotection is
dose-dependent. Water-soluble cyclodextrin-encapsulated
17β-estradiol (E4389; Sigma-Aldrich, St. Louis, MO, USA)
was dissolved in 0.9 % sodium chloride solution to be the
desired dose in 100 μl. Each vehicle control was rendered
so as to contain the same amount of hydroxypropyl cyclo-
dextrin as its corresponding 17β-estradiol treatment.
Regional renal cortical blood flow measurement
We measured regional renal cortical blood flow (RRCBF)
in the peri-arrest period. A laser Doppler flow probe
(Moor Instruments, Wilmington, DE, USA) was placed
perpendicular to the surface of the right kidney via a flank
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incision and optimally positioned for maximal signal.
Laser Doppler flow was measured and recorded 5 min
before CA, immediately before CA, every minute during
CA, and every 5 min after CA for 45 min after ROSC for
each animal treated with 17β-estradiol or vehicle at
15 min after ROSC. Fifty minutes after ROSC, arterial
blood was aspirated from the left ventricle for blood gas
assessment.
Transcardial perfusion and tissue sampling
Twenty-four hours after CA/CPR, thoracotomy was per-
formed under deep anesthesia. After blood sampling,
mice were perfused with saline, and the right kidney was
snap-frozen in liquid nitrogen and stored at −80 °C until
immunoblotting. Subsequently, mice were perfused with
4 % paraformaldehyde and then the left kidney was har-
vested for histological assessment.
Evaluation of serum urea nitrogen, serum creatinine, and
serum estradiol levels
A point-of-care enzyme-coupled analyzer (Abaxis Medical
Diagnostics, Union City, CA, USA) was used to measure
serum urea nitrogen (sUN) and serum creatinine (sCr).
17β-estradiol concentrations were measured by using
radioimmunoassay as previously described [12]. The GDN
244 antibody was used for radioimmunoassay [24]. The
overall inter-assay variation for 17β-estradiol extraction
radioimmunoassay was less than 15 %, and the intra-assay
variation was less than 12 %.
Histological evaluation of tubular injury
An observer blinded to treatment and sex assessed
histological damage by using rigorous unbiased stereol-
ogy. After fixation, 6-μm sagittal sections from the kid-
ney were sampled 160 μm apart and then stained with
Flouro-Jade B (Histo-Chem, Jefferson, AK, USA), which
stains necrotic cells bright green. Histological damage
was determined in accordance with the Cavalieri princi-
pal of unbiased stereology by using Visiopharm Inte-
grator Software (Visiopharm, Hørsholm, Denmark) and
delineating the total kidney area and applying superim-
posed grids consisting of two marks in a fixed relation
(4:64) randomly onto a field of view. The estimated
volume fraction of necrotic tubules was calculated as
follows:
Volume necrotic tubules ðVNTÞ
¼
X
Marks ðnecrotic tubulesÞ=
X
Marks ðkidneyÞ  16
The sampling intensity was decided according to our
previous study to obtain precise estimation with coeffi-
cient of error of less than 0.1 by using the formula of
Gundersen et al. [25]. The coefficients of error for the
necrotic tubules and the reference area in our study
were 0.08 and 0.05, respectively.
Immunoblotting
Expression of ERα and G protein-coupled estrogen re-
ceptor (GPER) in homogenates of the entire right kidney
obtained 24 h after CA/CPR were measured by using
rabbit polyclonal anti-ERα (clone HC-20; Santa Cruz
Biotechnology, Inc., Dallas, TX, USA) and anti-GPER
(clone N-15; Santa Cruz Biotechnology, Inc.) antibodies.
To eliminate any effect of exogenously administered es-
tradiol, this assay was performed only in vehicle-treated
mice. Mouse monoclonal anti-vinculin (clone cp74;
CalBiochem/EMD Millipore, Billerica, MA, USA) was
used as loading control. Secondary antibodies were anti-
mouse horseradish peroxidase (HRP) and anti-rabbit-HRP
from GE Healthcare (Little Chalfont, Buckinghamshire,
UK) and Cell Signaling Technology (Danvers, MA, USA),
respectively. Tissue was homogenized in ice-cold radioim-
munoprecipitation assay buffer (ThermoFisher Scientific,
Waltham, MA, USA) containing protease inhibitor cock-
tail (Sigma-Aldrich) and PhosSTOP phosphatase inhibitor
cocktail (Roche, Indianapolis, IN, USA). Protein concen-
tration was measured by using the BCA protein assay
(ThermoFisher Scientific). Western blots were performed
as previously described [26]. Primary antibodies were used
at a dilution of 1:50 (ERα), 1:500 (GPER), or 1:2000 (vin-
culin) in 5 % bovine serum albumin (BSA) in tris-buffered
saline with Tween-20 (TBST) (25 mM Tris, 1 M NaCl,
1 % Tween 20). Secondary antibodies were diluted 1:2000
(ERα), 1:5000 (GPER), or 1:15,000 (vinculin) in 5 % BSA
in TBST.
Statistical analysis
Statistical significance was inferred from a P value of less
than 0.05. Two-group two-treatment analyses were per-
formed by using two-way analysis of variance with post
hoc Sidak’s test. Categorical outcomes were assessed by
using Fisher’s exact test or chi-squared test, as appro-
priate. Analysis of differences in estrogen expression
between young and aged mice was performed via unpaired
t test. All results are presented as mean ± standard devi-
ation. Analysis was performed with Prism 6.0 software
(GraphPad Software, Inc., La Jolla, CA, USA).
Results
Male mice are more vulnerable to renal injury than
female mice after CA/CPR
To evaluate the severity of AKI after CA/CPR according
to sex and age, male and female C57BL/6 young and
middle-aged mice were subjected to 8 min of CA.
Twenty-four hours after CPR, a blood sample was col-
lected and kidney was harvested. Figure 1 summarizes
the renal injury 24 h after CA/CPR according to sex and
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age. CA/CPR caused renal injury in a sex-specific man-
ner. In surgically naïve animals, sUN and sCr were
equivalent between male and female (sUN: 28 ± 2.8 ver-
sus 30 ± 3.5, P = 0.17; sCr: 0.23 ± 0.08 versus 0.22 ± 0.04,
P = 0.73; and volume of necrotic tubules (VNT): 1.3 ±
1.8 versus 3.4 ± 2.2, P = 0.15, male versus female). Young
males developed greater renal injury than young females
after CA/CPR (sUN: 159 ± 64 versus 62 ± 29, P < 0.01;
sCr: 0.77 ± 0.33 versus 0.35 ± 0.17, P < 0.01; and VNT:
14 ± 1.9 versus 8.9 ± 4.8, P < 0.01, male versus female). In
middle-aged males, functional renal injury was greater
than that of females after CA/CPR (sUN: 187 ± 42 versus
101 ± 66, P < 0.01 and sCr: 1.7 ± 0.6 versus 0.63 ± 0.4,
P < 0.01). Tubular necrosis, however, was equivalent
between male and female middle-aged mice (VNT:
19 ± 3.1 versus 20 ± 5.8, P = 0.76). In summary, young
males suffer greater renal injury than young females
after CA/CPR. Middle-aged males also demonstrate
more severe post-ischemic renal dysfunction than
middle-aged females; however, the severity of tubular
necrosis is the same.
Dose-dependent renoprotection by post-arrest
administration of 17β-estradiol in young males
To determine the effect of acutely injected exogenous
estrogen on AKI, male young mice were subjected to
8 min of CA and then resuscitated. Fifteen minutes after
ROSC, 0.5, 5, or 10 μg of 17β-estradiol or vehicle was
injected intravenously. Figure 2 summarizes the findings
of the dose-escalation study in young male mice. Estrogen
dose-dependently reduces renal injury. Ten micrograms
of 17β-estradiol reduced sCr, sUN, and VNT by 30 %,
41 %, and 31 %, respectively. Therefore, this dose was
selected for the continuation of the study.
Renal blood flow is not altered by estrogen
administration following CA/CPR
To evaluate potential acute systemic effects of estrogen,
we measured RRCBF during and after CA/CPR and col-
lected blood samples for arterial blood gas analysis in
Fig. 1 Cardiac arrest and cardiopulmonary resuscitation (CA/CPR)
caused renal injury in a sex- and age-specific manner. Blood and
tissue samples were collected 24 h after CA/CPR in young (10–15
weeks) or middle-aged (43–48 weeks) male or female mice. CA/CPR
caused renal injury in a sex- and age- specific manner. In young
animals, female sex reduced serum urea nitrogen (a), serum creatinine
(b), and necrotic tubules (c). In middle-aged animals, female sex
reduced serum urea nitrogen (a) and serum creatinine (b) but not
necrotic tubules (c). Data are presented as mean ± standard deviation,
n = 6–10 per group. *P < 0.05 versus same age different sex, #P < 0.05
versus same sex different age. Data were analyzed by using two-way
analysis of variance with post hoc Sidak’s test. Aging did not alter
baseline renal function in naïve mice; therefore, we combined young
and middle age naïve mice
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separate cohorts. Figure 3 and Table 1 summarize the
results of experiments to measure RRCBF and metabolic
parameters in the immediate period following CA/CPR
and estrogen administration. There were no significant
differences in RRCBF or metabolic parameters between
groups.
Sex difference in the severity of AKI after CA/CPR and the
effect of post-arrest administration of 17β-estradiol
To investigate whether there are sex differences in the
effect of acutely administered estrogen on AKI after CA/
CPR, young male and female mice were subjected to
CA/CPR and administered 10 μg of either 17β-estradiol
or vehicle 15 min after ROSC. Table 2 summarizes the
baseline and resuscitation data for this protocol. Females
required slightly greater resuscitation time and epineph-
rine than males, but the mortality was not different (time
to resuscitate: 123 ± 33 versus 155 ± 30 sec, P < 0.05; epi-
nephrine dose: 0.52 ± 0.1 versus 0.73 ± 0.1 μg/g body
weight, P < 0.05; mortality: 32 % versus 26 %, P = 0.58,
n = 30 and 28, males versus females). Figure 4 illus-
trates the effect of estrogen on AKI in both sexes,
and Fig. 5 presents representative histologic images.
Males suffered greater injury than females, and sex
represented 23 % of the total variation in sUN, 25 %
in sCr, and 35 % in VNT. Estrogen reduced injury,
representing 13 % of the total variation in sUN, 7.2 %
in sCr, and 6.4 % in VNT. Post hoc comparison demon-
strates that estrogen is renoprotective in males only. Thus,
in young male mice, acutely injected estrogen after ische-
mic insult ameliorates AKI. Young female did not suffer
renal injury after 8 min of CA and were not affected by
the post-arrest administration of estrogen.
Estrogen is acutely renoprotective in old mice of both
sexes
To address the effect of aging on the renoprotective ef-
fect of estrogen according to sex, we tested 17β-estradiol
administration in aged mice in both sexes. Eight-minute
Fig. 2 17β-estradiol exerted a dose-dependent renoprotective effect
after cardiac arrest and cardiopulmonary resuscitation (CA/CPR) in
young males. Blood and tissue samples were collected 24 h after
CA/CPR in young male intravenously injected with 0.5, 5, or 10 μg
of 17β-estradiol or vehicle 15 min after return of spontaneous
circulation. Post-arrest administration of 17β-estradiol exerted a
dose-dependent renoprotective effect. At 0.5 μg, 17β-estradiol
administration exerted no apparent effect on renal injury 24 h after
CA/CPR. Five micrograms caused significant reduction in serum
creatinine (b) but not serum urea nitrogen (a) and necrotic tubules
(c). At a dose of 10 μg, 17β-estradiol significantly reduced serum
urea nitrogen (a), serum creatinine (b), and necrotic tubules (c) by 41 %,
30 %, and 31 %, respectively. Data are presented as mean ± standard
deviation, n = 8–15, *P< 0.05 by two-way analysis of variance with post
hoc Sidak’s test. EST 17β-estradiol-treated mice, VEH vehicle-treated mice
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CA/CPR was 100 % lethal in mice of extreme age (n = 7).
Therefore, we reduced the CA time from 8 to 7 min.
Seven-minute CA/CPR in aged mice was associated with
similar resuscitation and mortality to 8 min CA/CPR in
young mice (age: 83 ± 2.6 versus 12 ± 1.5 weeks; time to
resuscitate: 136 ± 32 versus 138 ± 35 sec, P = 0.78; mortal-
ity: 21 % versus 29 %, P = 0.32, n = 47 and 82, aged versus
young). There was no sex difference in these parameters
(time to resuscitate: 137 ± 31 versus 135 ± 34 sec, P =
0.86; mortality: 30 % versus 10 %, P = 0.07, n = 26 and
21, males versus females). These resuscitation data
are detailed in Table 2. Figure 6 illustrates the effect of
estrogen on AKI in both sexes in aged mice. Overall, in
aged mice, estrogen significantly reduced sUN, sCr, and
VNT (representing 23 %, 16 %, and 40 % of total variation,
respectively). Post hoc comparison showed significant re-
duction of sCr (80 %) and VNT (73 %) in aged males.
In this protocol, females treated with 17β-estradiol
demonstrated reduced VNT relative to vehicle (a
51 % reduction, P < 0.05), and a protective trend was
evident in sUN (45 %, P = 0.08). Therefore, in mice of
advanced age, there was no significant effect of sex
on renal injury.
Serum estrogen levels in aged female mice are the same
as physiologic levels in male mice 24 h after CA/CPR
We measured serum estradiol levels in estrogen- and ve-
hicle-treated animals 24 h after CA/CPR to determine
whether prolonged differences in estradiol serum levels
could contribute to renal outcome. In young female mice,
serum levels of estradiol varied considerably in a manner
consistent with reproductive cycling (62 ± 123 pg/ml,
n = 23). Serum estradiol concentration was negligible in
aged females (16 ± 9 pg/ml, n = 17, P < 0.05 versus young
females) and the same as that in young and old males (17
± 10 and 11 ± 8 pg/ml, n = 30 and 17). Serum estradiol
was not different 24 h after treatment whether the animals
were treated with 17β-estradiol or vehicle, suggesting
that it returned to physiologic levels prior to 24 h after
administration.
Estrogen receptor expression is upregulated in aged
females compared with young females 24 h after CA/CPR
To elucidate the mechanism of the observed difference
in effect of post-arrest estrogen between young and old
females and between males and females, we measured
levels of the two ERs expressed in renal tissue [27, 28]
(ERα and GPER) after CA/CPR. In aged females, the
expression of ERα was increased compared with young
females (P = 0.01, Fig. 7b, f ). By contrast, aged males
demonstrated a significant increase in the expression of
GPER compared with young males (P < 0.01, Fig. 7c, e).
Discussion
There are three major findings of the present study.
First, the advantage of female sex against AKI after
whole-body ischemia, which is consistently observed
both in our previous study and in the present study,
weakens with age. Second, estrogen exerts renoprotec-
tive effects even when administered after resuscitation
from CA. To the best of our knowledge, this is the first
study to demonstrate that exogenous estrogen acts as a
potent renoprotective agent when administered in a
clinically relevant manner, after whole-body ischemia-
reperfusion. Third, estrogen injection improves renal
outcome in males, but reproductively intact young fe-
male are not affected because injury is small, whereas in
Fig. 3 Regional renal cortical blood flow (RRCBF) is not altered by
estrogen administration. Laser Doppler flow of RRCBF was measured
in the peri-arrest period for each animal treated with 17β-estradiol
or vehicle at 15 min after return of spontaneous circulation (ROSC).
The average of the measurement taken 5 min before and immediately
before cardiac arrest (CA) served as baseline flow, and all measurements
were described as percentage of baseline flow to minimize variation
between animals. RRCBF values are not affected by administration of
17β-estradiol. RRCBF dropped immediately to nonperfusing values on
CA. RRCBF remained low after ROSC for 15 min and then gradually
returned to the baseline in the 45-min follow-up period. There
was no significant difference in RRCBF between estrogen-treated
and vehicle-treated animals at any point. Data are presented as
mean ± standard deviation, n = 6 or 7 per group
Table 1 Post-CA/CPR arterial metabolic values
Treatment pH PCO2 pO2 HCO3
− Hb K+ Na+ Lac Ca++ BE
Estrogen 6.9 (0.1) 47.0 (16.9) 226 (127) 9.8 (3.2) 13.6 (0.5) 5.1 (0.6) 145 (2.6) 8.7 (2.9) 1.1 (0.1) −19.8 (4.3)
Vehicle 6.8 (0.2) 54.1 (19.4) 141 (104) 8.6 (3.7) 14.4 (1.0) 5.8 (0.7) 147 (3.8) 10.3 (4.5) 1.1 (0.1) −22.4 (5.3)
Data are presented as mean (standard deviation)
CA/CPR cardiac arrest and cardiopulmonary resuscitation
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aged mice, estrogen is beneficial to both sexes. Taken
together, these three findings indicate that post-arrest
estrogen administration is renoprotective in a sex- and
age-dependent manner.
We confirmed that females enjoy relative renoprotec-
tion after CA as previously reported [12, 13, 21] and ex-
tend this finding with the finding that this advantage
weakens in middle age as tubular necrosis becomes
equivalent to that of males. Functional measures of in-
jury are still reduced in middle-aged females. Previous
studies have demonstrated that female mice enter repro-
ductive senescence by 44–64 weeks [29]. We chose to
assess sex difference in middle age precisely because
some females, but not all, may have ceased reproductive
cycling, thus the mixed finding was expected. To further
evaluate the effect of age and reproductive cycling, we
used mice of extreme age (78–87 weeks). These aged fe-
males lose their advantage both in renal function and in
tubular cell death. Serum estradiol levels in aged females
decreased to the same level as physiologic level of male
mice. Taken together, these data suggest that females
lose renoprotection according to age because of chan-
ging exposure to estrogen. This would recapitulate our
previous findings using ovariectomized young mice [12,
13]. However, whether intact females lose their advan-
tage according to reproductive senescence remains a
vital translational question, and we directed this study at
this query. Our findings are in line with previous litera-
ture studying age-dependent progression of renal dam-
age in female mice. Urbieta-Caceres et al. suggested that
aging-induced renal interstitial fibrosis in female mice
was mediated by loss of endogenous estrogen [30].
Zheng et al. reported that female mice developed
progressive glomerulosclerosis after menopause [31]. Al-
though we did not find any difference between young
and aged female surgically naïve animals, those struc-
tural abnormalities caused by aging may increase suscep-
tibility to acute ischemic insult in aged females.
The present study demonstrates for the first time a
beneficial effect of estrogen on AKI after CA/CPR in
male mice. To assess critical translational benefit of es-
trogen in male mice, we chose the timing of injection at
15 min after ROSC and evaluated three doses. We chose
CA/CPR as our model for ischemia-reperfusion injury
because it replicates key features of clinical ischemia-
reperfusion, making it clinically relevant. First, it replicates
the most common cause of clinical AKI, whole-body
hypoperfusion [4]. Second, as can be seen from our data,
CA/CPR produces mild-moderate renal injury similar to
that seen in clinical ischemia-reperfusion injury. Third,
other groups have found that CA/CPR may more closely
model ischemic inflammatory, immune, and renal arterial
flow changes than occlusion of the renal pedicle, a widely
used model of renal ischemia [32, 33]. Our data indicate a
dose-dependent reduction of renal injury by post-ischemic
administration of estrogen. In previous experiments using
young female mice exposed to CA/CPR, we found that
ovariectomy significantly increased injury and that estra-
diol treatment 7 days prior to ischemic insult, designed to
replicate physiologic levels, restored protection [12, 33].
Müller et al. found that increased mortality after focal
renal ischemia in male rats compared to female was re-
versed with estrogen treatment 7 days prior to the insult
[10]. Park et al. also reported that estrogen treatment
15 days before renal artery occlusion reduces the post-
ischemic increase of sUN and sCr in male mice [11].
Table 2 Baseline and resuscitation data according to age, sex, and treatment
Group Treatment Numbera Age, week Body weight, g Epinephrine dose,
μg/g body weight
Epinephrine dose, g CPR time, s Survival rate, %
Young male VEH 15 11.1 (0.4) 25.0 (1.6) 0.53 (0.09) 13.2 (2.0) 129 (29) 68
EST 15 11.2 (0.4) 25.1 (1.8) 0.51 (0.11) 12.7 (2.2) 118 (37) 68
P* 0.90 0.97 0.09 0.71 0.42 1
Young female VEH 14 12.5 (2.0) 19.7 (0.8) 0.75 (0.08) 14.8 (1.6) 158 (28) 64
EST 14 12.9 (1.7) 19.9 (1.1) 0.71 (0.11) 14.0 (1.9) 151 (33) 88
P* 0.58 0.94 0.99 0.42 0.75 0.10
Aged male VEH 8 83.8 (2.9) 34.9 (6.8) 0.42 (0.10) 14.3 (1.9) 136 (36) 71
EST 10 82.6 (3.1) 39.2 (8.6) 0.36 (0.09) 13.6 (1.5) 138 (27) 67
P* 0.26 0.26 0.11 0.33 0.87 0.60
Aged female VEH 9 81.4 (2.4) 29.1 (5.1) 0.51 (0.13) 14.2 (1.9) 142 (35) 100
EST 10 82.2 (1.4) 31.1 (4.3) 0.42 (0.09) 12.9 (2.1) 130 (35) 83
P* 0.38 0.33 0.11 0.16 0.44 0.49
Data are presented as mean (standard deviation)
CPR Cardiopulmonary resuscitation, VEH vehicle, EST 17β-estradiol
anumber of survives
*P values shown for Sidak’s multiple comparison test or chi-squared test when appropriate
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Takaoka et al. [34] and Tanaka et al. [35] demonstrated
with the renal pedicle occlusion model that male rats
injected with estrogen 15 min prior to reperfusion demon-
strated improved post-ischemic renal outcomes. On the
other hand, a recent study which employed intramuscular
injection of estrogen 3 days prior to renal ischemia-
reperfusion surgery found that estrogen’s protective effect
was limited to ovariectomized female rats and did not
protect male rats [36]. The discrepancy of these findings is
probably due to the heterogeneity of the experimental
model and the length of time of administration. Estrogen
dose varied according to the study (25 μg/kg × 7 days [10],
40–500 μg/kg × 14 days [11], 100 μg/kg × single dose [35]
and 500 μg × 3 days [36]); however, no prior study has
evaluated the effect of estrogen administration after reper-
fusion, either whole-body ischemia/reperfusion or renal
vascular occlusion. In the present study, only higher dose
of estrogen (400 μg/kg) injected during the early reper-
fusion phase improved the renal outcome in male mice.
Estrogens may exert a different mechanism of action
depending on the timing of injection, dose, and extent of
overall injury. Thus, it is notable that not all studies of
estrogen in CA have demonstrated a protective effect. A
recent study using a male rat model of ventricular fibrilla-
tion and resuscitation reported that estrogen administra-
tion did not result in beneficial myocardial effect or
impact survival. The survival rates 3 h after resuscitation
in this severe-injury model are 0 % versus 33 %, P = 0.32,
estrogen versus saline, for bolus injection and 63 % versus
100 %, P < 0.05, estrogen versus saline, for continuous in-
jection [37]. The present study uses a CA/CPR model
which demonstrates a mild injury and survival of more
than 65 % in order to assess renal outcome 24 h after
ROSC, and this may explain the apparently discordant
result.
Pre-ischemic estrogen alters outcome of focal renal
ischemia via nitric oxide and endothelin-1 [10, 34]. Be-
cause both of these mediators are believed to act on
renal blood flow, our findings that neither RRCBF nor
systemic metabolic parameters are affected by estrogen
Fig. 4 Sex difference in the severity of acute kidney injury after
cardiac arrest and cardiopulmonary resuscitation (CA/CPR) and the
effect of post-arrest administration of 17β-estradiol. Blood and tissue
samples were collected 24 h after CA/CPR in young (10–15 weeks)
male or female mice intravenously injected with 10 μg of 17β-
estradiol or vehicle 15 min after return of spontaneous circulation.
There was a sex difference in estrogen-mediated amelioration of
renal injury following CA/CPR in young mice. Estradiol treatment
significantly reduced serum urea nitrogen (a), serum creatinine (b),
and tubular cell death (c) in males (triangle), but young females were
not affected, because injury was small (circle). Data are presented as
mean ± standard deviation, n = 14 or 15 per group, *P < 0.05 by
two-way analysis of variance with post hoc Sidak’s test. EST
17β-estradiol-treated mice, VEH vehicle-treated mice
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during the post-arrest period suggest that the mechan-
ism of acute renoprotection by post-arrest estrogen may
be distinct from that of chronic or pre-ischemic admin-
istration. Since no prior study addresses post-treatment
with estrogen in the kidney, we note that after experi-
mental stroke estrogen exerted a protective effect due to
enhanced cerebral blood flow [38, 39]. In our whole-
body ischemia model, we found that estrogen does not
alter RRCBF or systemic metabolic parameters in the
recovery period up to 45 min following CA/CPR. We
cannot eliminate the possibility that renal medullary but
not renal cortical blood flow is affected by estrogen, as it
is reported that even though cortical blood flow fully re-
covers in 30–45 min after bilateral occlusion of the renal
arteries and veins and reperfusion, medullary blood flow
remains compromised for prolonged periods that are
associated with a long-term decline in renal function
[40, 41]. However, this investigation is focused on acute,
24-h outcomes, and estrogen mediation of long-term
outcome was not assessed in this study. Another possi-
bility is that the use of isoflurane in our study confounds
the evaluation of blood flow, as it is a vasodilator. An
additional possible limitation regarding the use of iso-
flurane is its well-characterized renoprotective effect
[42]. It is not possible to perform our study without
anesthesia; we carefully designed experiments to exclude
differential effect of either vasodilatory or renoprotective
properties of isoflurane. As all animals received the same
Fig. 5 Representative photomicrographs of Flouro-Jade B-stained kidney section 24 h after cardiac arrest and cardiopulmonary resuscitation.
Mouse kidneys were perfusion-fixed and removed 24 h after cardiac arrest and cardiopulmonary resuscitation and then stained with Flouro-Jade
B, which stains early necrotic cells bright green. a Young female vehicle. b Young female estrogen. c Young male vehicle. d Young male estrogen.
e Aged female vehicle. f Aged female estrogen. g Aged male vehicle. h Aged male estrogen
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concentration of isoflurane, no observed effect can be
due to the influence of isoflurane alone.
In the present study, efficacy of post-ischemic estrogen
injection was observed amongst young mice only in
males. On the other hand, estrogen was renoprotective
in old mice of both sexes. In our previous studies, we
found that deletion of ERs α, β, and GPER did not inter-
fere with protection against renal injury from ischemia/
reperfusion when estrogen was administered for a week
prior to CA/CPR [12, 13]. In evaluating these findings,
we hypothesized that pre-ischemic and repeated dosing
of estrogen could protect the kidney through multiple
mechanisms mediated by more than one receptor; thus,
deletion of a single receptor would not abrogate the pro-
tective effect. As acute and chronic administrations of
estrogen are differentially protective in neurologic ische-
mia [43], this might also be the case in renal ischemic
injury. Thus, it is essential to evaluate involvement of
renal ERs in the effect we observed. Since aged females
are in a low-estrogen environment compared with young
females, we hypothesized that ER expression levels differ
between the two, and this might explain the different
response to the exogenous estrogen. We therefore mea-
sured renal ERα and GPER levels in animals not treated
with estrogen. We found that the expression of ERα in
aged females was increased compared with young fe-
males 24 h after CA/CPR. This finding in animals after
CA/CPR is similar to those of others: in surgically naïve
animals, ERα expression increases with age in renal tis-
sue [44]. Our finding is limited in that the 24-h time
point may not precisely replicate the levels present at
the time of reperfusion; therefore, the inference of
mechanistic association should be interpreted with cau-
tion. In heart [45] and brain [46, 47], ER activation re-
duces ischemic injury. In light of these findings and in
light of recent data indicating ERα as a mediator of pro-
tective estrogen signaling in female rats with pulmonary
hypertension-induced right ventricular failure [48], we
speculate (with the above limitations) that protective
acute estrogen effects in aged females are mediated at
Fig. 6 17β-estradiol after cardiac arrest and cardiopulmonary
resuscitation (CA/CPR) ameliorates renal injury in old mice of both
sexes. Blood and tissue samples were collected 24 h after CA/CPR in
aged (78–87 weeks) male or female mice intravenously injected with
10 μg of 17β-estradiol or vehicle 15 min after return of spontaneous
circulation. Unlike in young mice, in this group of mice at advanced
age, there was no significant effect of sex on renal injury. Estradiol
treatment significantly reduced serum creatinine (b) and tubular cell
death (c) in aged males (triangle) and tubular cell death (c) in aged
females (circle). Serum urea nitrogen was not affected by estrogen
treatment in either aged males or aged females (a). Data are presented
as mean ± standard deviation, n = 8–10 per group, *P < 0.05 by
two-way analysis of variance with post hoc Sidak’s test. EST
17β-estradiol-treated mice, VEH vehicle-treated mice
Ikeda et al. Critical Care  (2015) 19:332 Page 10 of 14
least in part by ERα, and further investigation will test
this hypothesis.
Sex differences in the expression of ER during aging
[44] and in neuroprotective effects of ER agonists have
been reported [49]. Broughton et al. found that GPER
expression was increased in the brain of male mice but
not of female mice after transient focal cerebral ischemia
[50] and that GPER activation worsens outcome in
males but that an opposite protective effect occurs in
females [49]. Interestingly, the expression of GPER in
kidney 24 h after CA/CPR was increased in aged male
compared with young male mice in our study. The
underlying mechanisms responsible for the estrogen’s pro-
tective effect to renal ischemic injury observed in our
study require further investigation, particularly with re-
gard to sex difference. Androgens, including testosterone,
are reported to increase the susceptibility of males to is-
chemic renal injury [10, 11]. Myocardial ischemia reper-
fusion injury in male rats aggravated cardiac damage
through androgen receptor [51]. The interaction of sex
hormones besides estrogen and their change in the aging
process might modify the effect of estrogen’s renoprotec-
tion in males. Together, these findings highlight the com-
plex nature of endogenous estrogen signaling, which may
A B
C D
E F
Fig. 7 Renal expression of ERα and GPER 24 h after cardiac arrest and cardiopulmonary resuscitation (CA/CPR). Aging is associated with increased
renal expression of ERα in female mice and GPER in male mice 24 h after CA/CPR. ERα and GPER expressions were determined in kidney
homogenates of young (10–15 weeks) or aged (78–87 weeks) male (a, c, e) or female (b, d, f) mice harvested after 24 h of CA/CPR by Western
blotting with subsequent quantification by densitometry. Densitometric analyses for ERα and GPER are shown in (a–d). Western blots including
homogenates from all animals (n = 8 or 9 per group) are shown in (e, f). Note the increase in ERα abundance in aged females (b, f) and increase
in GPER abundance in aged males (c, e). Data are presented as mean ± standard deviation, n = 8 or 9 per group, *P < 0.05 by unpaired t test. ER
estrogen receptor, GPER G protein-coupled estrogen receptor
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vary between different physiological and disease settings.
Sex should be considered in identification of the under-
lying mechanism responsible for the effect of estrogen.
In addition to the sex and age specificity of estrogen’s
renoprotective mechanisms, it is possible that estrogen
exerts its effect differently because of timing. We ac-
knowledge that most previous studies are designed in
the aspect of hormone replacement therapy, mostly in-
volving long-term drug pretreatment before experimen-
tal ischemia, and that more work is required to fully
evaluate the efficacy of estrogen as a potent therapeutic
agent. Our study, designed to evaluate efficacy of acute
and transient estrogen exposure, shows that the reno-
protective effect is rapid, exerted within 24 h of ischemia
reperfusion, perhaps sooner, suggesting one of the non-
nuclear, rapid actions of estrogen [45, 52]. The fact that
serum estradiol levels have returned to physiologic levels
within 24 h after estradiol injection reinforces the argu-
ment of estrogen’s rapid action. In our recent in vitro
study, we found that hyperpermeability of glomerular
endothelial cells after ischemia was prevented by estro-
gen in part through GPER [21]. Interestingly, in that
study, the significant decrease in glomerular permeability
by estrogen observed after 4 h of re-oxygenation was no
longer evident at 8 h, suggesting that estrogen’s effect is
acute and transient. Preserved glomerular barrier integ-
rity during the acute phase of reperfusion might prevent
subsequent tubular dysfunction and tubular cell death.
We did not assess whether post-arrest estrogen injection
alters glomerular permeability or GPER expression at an
early phase of reperfusion in the present study, which
was focused on whether estrogen exerted any acute
beneficial effect in renal ischemia. Further investigation
of glomerular permeability effects of estrogen in vivo
might delineate a mechanism of the protective effect we
observed. We did not find any difference in 24-h survival
rate between estrogen-treated animals and vehicle-treated
animals in our potassium-induced CA model (76 % versus
66 %, P = 0.30, estrogen versus vehicle), and estrogen-
treated animals had less kidney injury.
Conclusions
In summary, we report that estrogen injection shortly
after resuscitation from CA ameliorates renal injury in
young males. Young females were not protected by es-
trogen, because of reduced renal injury from CA/CPR
itself relative to males and aged females. In aged females,
the protective effect of exogenous estrogen may be re-
covered with loss of endogenous estrogen.
The magnitude of the effect in our model offers prom-
ise for future translational study. For successful transla-
tion, an observed preclinical effect should match with
the population at risk for the disease. Our study suggests
that acute, estrogen-mediated renoprotection is selective
to males and aged females, precisely the population at
risk for clinical AKI. Our findings suggest that further
investigation of estrogen-mediated renoprotection should
focus on rapid effects and whether in aged animals these
are mediated thorough cognate ERs.
Key messages
 Aging reduces the female advantage in renal
outcome after whole-body ischemia reperfusion
injury.
 When given in a clinically relevant manner after
cardiac arrest and cardiopulmonary resuscitation,
estrogen reduces renal injury in male and aged
female mice.
 This study provides early evidence that efforts to
translate this first demonstration of an estrogenic
acute post-resuscitation renoprotective effect may
best be focused on rapid effects which in the aged
may be mediated by cognate estrogen receptors.
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